Laurion Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laurion Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.47M	Buy	+4,431	New	+$1.51M	0.06%	233
2020 Q3	–	Sell	-6,013	Closed	-$891K	–	813
2020 Q2	$891K	Buy	+6,013	New	+$811K	0.01%	492
2019 Q1	–	Sell	-9,341	Closed	-$681K	–	831
2018 Q4	$681K	Buy	+9,341	New	+$718K	0.01%	645
2018 Q1	–	Sell	-121,735	Closed	-$15.5M	–	1305
2017 Q4	$15.5M	Buy	+121,735	New	+$15.3M	0.08%	255
2017 Q1	–	Sell	-9,450	Closed	-$354K	–	1267
2016 Q4	$354K	Buy	+9,450	New	+$396K	﹤0.01%	900

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's ALNY Position: Q1 2026 in Review

Laurion Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 4,431 shares worth $1.47M. The stake represents 0.06% of the portfolio and ranks #233 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in ALNY as recently as Q2 2020.

Laurion Capital Management first reported a position in ALNY in Q4 2016 and has held it in 5 quarters since. The position peaked at $15.5M in Q4 2017. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Laurion Capital Management held 4,431 shares of Alnylam Pharmaceuticals worth $1.47M as of Q1 2026.
Alnylam Pharmaceuticals was a new Laurion Capital Management position in Q1 2026.
Alnylam Pharmaceuticals made up 0.06% of Laurion Capital Management's portfolio in Q1 2026, its #233 holding.
Laurion Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
Laurion Capital Management's Alnylam Pharmaceuticals position peaked at $15.5M in Q4 2017.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.